Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bortezomib - Janssen-Cilag/Takeda Oncology

Drug Profile

Bortezomib - Janssen-Cilag/Takeda Oncology

Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Bayer; Childrens Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Indiana University; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Millennium; Millennium Pharmaceuticals; New York University School of Medicine; Singapore General Hospital; Takeda Oncology; Teva Pharmaceutical Industries; University of Michigan Comprehensive Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Multiple myeloma; Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Registered B-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Glioma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Malignant melanoma; Neuroblastoma; Pancreatic cancer
  • Discontinued Adenocarcinoma; Amyloid light-chain amyloidosis; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Prostate cancer; Rheumatoid arthritis; T-cell prolymphocytic leukaemia

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 28 Aug 2019 Millennium Pharmaceuticals completes a phase II trial in Non-small cell lung cancer (Late-stage disease, Recurrent) in USA (SC) (NCT01833143)
  • 14 May 2019 H. Lee Moffitt Cancer Center and Research Institute and Millennium Pharmaceuticals completes a phase II trial for Multiple Myeloma (Combination therapy) in USA (NCT00948922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top